No risk of Guillain–Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies


  • Weiling Katherine Yih,

    Corresponding author
    • Centers for Disease Control and Prevention, Atlanta, GA, USA; Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • Eric Weintraub,

  • Martin Kulldorff

  • Institutions providing the data: Group Health Cooperative (Washington State), Harvard Vanguard Medical Associates and Harvard Pilgrim Health Care (Massachusetts), HealthPartners (Minnesota), Kaiser Permanente of Colorado, Kaiser Permanente of Northern California, Kaiser Permanente of Southern California, Marshfield Clinic (Wisconsin), and Northwest Kaiser Permanente (Oregon and Washington)
  • Prior presentations: These results were presented at a meeting of the Global Collaborative Network for Vaccine Safety Studies organized by the Fondation Mérieux in Annecy, France in March 2011 and at an annual meeting of the Vaccine Safety Datalink in Portland, Oregon in April 2011.

W. K. Yih, Harvard Pilgrim Health Care Institute. and Harvard Medical School E-mail:

No abstract is available for this article.